Authorized purpose: ScreenDx provides adjunctive positive/negative assessment of interstitial lung findings on DICOM lung CT in patients older than 22 years to support referral for clinical assessment; it does not rule in or rule out lung fibrosis or replace standard diagnosis.
Clinical role
Adjunctive detection supporting referral and clinical assessment.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: Not a rule-in or rule-out test for lung fibrosis and not a replacement for current diagnostic methods. Use results with history, symptoms, other diagnostic tests, and professional judgment; age must be greater than 22 years.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ScreenDx provides adjunctive positive/negative assessment of interstitial lung findings on DICOM lung CT in patients older than 22 years to support referral for clinical assessment; it does not rule in or rule out lung fibrosis or replace standard diagnosis.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: DICOM-compliant lung CT scans submitted through an image-receiver API; ingestion selects appropriate cases for analysis.
Who uses it?Intended users: Clinicians qualified in the care of lung disease.
What does the software produce?Output: Binary Positive (Suggestive of ILD)/Negative result; results are stored and transmitted by an output API to assigned users. No diagnostic information or image localization is generated.
What is its most important limitation?Key limitation: Not a rule-in or rule-out test for lung fibrosis and not a replacement for current diagnostic methods. Use results with history, symptoms, other diagnostic tests, and professional judgment; age must be greater than 22 years.
Clinical takeaway. Clinical role: ScreenDx provides adjunctive positive/negative assessment of interstitial lung findings on DICOM lung CT in patients older than 22 years to support referral for clinical assessment; it does not rule in or rule out lung fibrosis or replace standard diagnosis.
Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter pivotal study of 3,018 unique patients, enriched to 23% positive lung-fibrosis diagnoses, using independently recorded clinical diagnoses as reference. The baseline reports sensitivity 91.4% and specificity 95.2%; an additional 2,482-case low-prevalence dataset is separately described in the FDA summary.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ScreenDx provides adjunctive positive/negative assessment of interstitial lung findings on DICOM lung CT in patients older than 22 years to support referral for clinical assessment; it does not rule in or rule out lung fibrosis or replace standard diagnosis.
Binary Positive (Suggestive of ILD)/Negative result; results are stored and transmitted by an output API to assigned users. No diagnostic information or image localization is generated.
Not a rule-in or rule-out test for lung fibrosis and not a replacement for current diagnostic methods. Use results with history, symptoms, other diagnostic tests, and professional judgment; age must be greater than 22 years.
Retrospective multicenter pivotal study of 3,018 unique patients, enriched to 23% positive lung-fibrosis diagnoses, using independently recorded clinical diagnoses as reference. The baseline reports sensitivity 91.4% and specificity 95.2%; an additional 2,482-case low-prevalence dataset is separately described in the FDA summary.
Exact FDA submission
Checked 2026-09-05
Regulatory study context; no independent efficacy or referral-outcome claim.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective multicenter pivotal study of 3,018 unique patients, enriched to 23% positive lung-fibrosis diagnoses, using independently recorded clinical diagnoses as reference. The baseline reports sensitivity 91.4% and specificity 95.2%; an additional 2,482-case low-prevalence dataset is separately described in the FDA summary.
FDA source
Exact FDA submission
Checked 2026-09-05
Regulatory study context; no independent efficacy or referral-outcome claim.
91.4% (95% CI 89.0-93.3%) in the 3,018-case pivotal dataset
FDA source
Exact FDA submission
Checked 2026-09-05
ScreenDx as submitted in K241891; CT interstitial-lung-finding classification against clinical diagnoses, 23% positive prevalence. This is distinct from development and external-publication cohorts.
95.2% (95% CI 94.3-96.1%) in the 3,018-case pivotal dataset
FDA source
Exact FDA submission
Checked 2026-09-05
ScreenDx as submitted in K241891; CT interstitial-lung-finding classification against clinical diagnoses, 23% positive prevalence. This is distinct from development and external-publication cohorts.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ScreenDx FDA pivotal standalone evaluation
DesignRetrospective multicenter standalone study
Population3,018 unique patients; 694 positive lung-fibrosis diagnoses and 2,324 negatives; multiple CT manufacturers and protocols.
Scopeexact submission
Tested versionScreenDx in K241891; numeric build and operating cut-off not established in reviewed text
Samplen=3018
IndependenceIndependence not established
K241891
Reference diagnoses used clinical, radiological, laboratory and/or pathological assessments. Test patients did not overlap training; enriched prevalence limits translation to incidental-screening predictive values.
ScreenDx, an artificial intelligence-based algorithm for the incidental detection of pulmonary fibrosis
DesignDevelopment, tuning, and external cohort validation
PopulationDevelopment cohort 3,658 CT cases; US tuning cohort 381; separate international external-validation cohort 683.
Scopeproduct family
Tested versionScreenDx; exact build and equivalence to K241891 not established in the abstract
Samplen=683
IndependenceSponsor or vendor study
PMID:40020875 · DOI:10.1016/j.amjms.2025.02.011
Abstract and conflict disclosures reviewed through the live PubMed search result after a direct-page challenge. Imvaria funded the work and employed three authors. Metrics are not transferred to the exact-submission dossier.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compliant lung CT scans submitted through an image-receiver API; ingestion selects appropriate cases for analysis.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Image Receiver API accepts cases from compliant systems such as DICOM/PACS. Output API integrates with hospital/clinic notification software such as an EHR or messaging system; the institution controls the output workflow.
Scope: Exact FDA submission. Named interface protocols and local vendor-version compatibility are not established by these examples.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. FDA describes APIs and an ingestion/analysis system but does not establish the current customer's hosting topology, region, or retention terms.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-05 ·
Returned objects
Source context, not route validation: Binary Positive (Suggestive of ILD)/Negative result; results are stored and transmitted by an output API to assigned users. No diagnostic information or image localization is generated.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Binary Positive (Suggestive of ILD)/Negative result; results are stored and transmitted by an output API to assigned users. No diagnostic information or image localization is generated.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Image Receiver API accepts cases from compliant systems such as DICOM/PACS. Output API integrates with hospital/clinic notification software such as an EHR or messaging system; the institution controls the output workflow.
Exact FDA submission
Checked 2026-09-05
Named interface protocols and local vendor-version compatibility are not established by these examples.
The FDA-cleared PCCP permits defined model-architecture and classification cut-off updates using prescribed data management, retraining, performance evaluation, and update procedures.
Exact FDA submission
Checked 2026-09-05
This establishes the regulatory change-control scope only. Installed model, notification of updates, local acceptance, and production monitoring remain site/vendor questions.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
27Fields reviewed
12Source classes checked
3Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored metadata for all three papers screened. PMID 40020875 abstract and disclosures support a product-family contextual study; exact build linkage is unresolved. PMID 37822853 and PMID 41314436 are relevant pulmonary-fibrosis/ILD leads but full methods/version linkage were not reviewed and no results were promoted. No stored trial candidates. The current discovery snapshot contains 3 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, vendor product page, literature index, peer reviewed literature, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The reviewed official ScreenDx page requests contact and does not specify a scoped price. Confirm per-case or enterprise terms, integration, minimum volume, and support; procurement research is incomplete.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Imvaria reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.
Deployment: Not verified - checked 2026-09-05 - Exact FDA submission
FDA describes APIs and an ingestion/analysis system but does not establish the current customer's hosting topology, region, or retention terms.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
No dated, scoped commercial security attestation was reviewed. Data transfer, storage, deletion, access control, and incident-response terms remain to be obtained.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
The vendor describes background automation, but clinician training and referral-ownership onboarding commitments were not established.
eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.
Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.
Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.
Authorized purpose: Adjunctive pulmonary nodule detection and measurement, including temporal comparison, in chest CT screening of asymptomatic adults aged at least 55 years.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.